Search Results - "García, J. Polo"

Current situation of direct oral anticoagulants in primary care in Spain: Positioning of SEMERGEN in 2023 by Polo-García, J, Pallares-Carratalá, V, Turegano-Yedro, M, Romero-Vigara, J C, Prieto-Díaz, M A, Cinza-Sanjurjo, S

“…Oral anticoagulation is the key to reduce the risk of stroke in atrial fibrillation. Although vitaminK antagonists (VKA) have classically been used for this…”
Get full text

Factors associated with cardiovascular risk and cardiovascular and renal disease in the IBERICAN study: Final results by Cinza-Sanjurjo, S, Micó-Pérez, R M, Velilla-Zancada, S, Prieto-Díaz, M A, Rodríguez-Roca, G C, Barquilla García, A, Polo García, J, Martín Sánchez, V, Llisterri Caro, J L

“…OBJECTIVETo analyse the prevalence in clinical practice of cardiovascular risk factors (CVRF) and cardiovascular disease (CVD), as well as their causal…”
Get full text

Prevalence, impact and management of hypertension-mediated organ damage in type 2 diabetes patients by Romero-Secin, A.A., Díez-Espino, J., Prieto-Díaz, M.A., Pallares-Carratala, V., Barquilla-García, A., Micó-Pérez, R.M., Polo-García, J., Velilla-Zancada, S.M., Martín-Sanchez, V., Segura-Fragoso, A., Ginel-Mendoza, L., Arce-Vazquez, V.M., Cinza-Sanjurjo, S.

“…To determine the prevalence, impact and management of hypertension-mediated organ damage (HMOD) according to the presence of type 2 diabetes (T2DM). IBERICAN…”
Get full text

Description of the sample, design and methods of the study for the identification of the Spanish population at cardiovascular and renal risk (IBERICAN) by Cinza Sanjurjo, S, Llisterri Caro, J L, Barquilla García, A, Polo García, J, Velilla Zancada, S, Rodríguez Roca, G C, Micó Pérez, R M, Martín Sánchez, V, Prieto Díaz, M Á

“…Cardiovascular diseases (CVD) are the leading cause of death in Spain, and although the incidence rates have been declining for years due to improvements in…”
Get full text

SEMERGEN positioning on approaching chronic heart failure in primary care by Castillo Moraga, M J, Turégano-Yedro, M, Pallarés-Carratalá, V, Seoane-Vicente, M C, Serrano Cumplido, A, Ruiz-García, A, Martin-Rioobó, E, Escobar-Cervantes, C, Polo-García, J, Barrios, V

“…Heart failure (HF) is a public health problem that generates a large healthcare burden both in hospitals and in Primary Care (PC). The publication of numerous…”
Get full text

Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain by Polo García, J, Vargas Ortega, D, Formiga, F, Unzueta, I, Fernández de Cabo, S, Chaves, J

“…Abstract Objective In non-valvular atrial fibrillation (NVAF) with embolic risk, the guidelines recommend oral anticoagulation (OAC), although not all patients…”
Get full text

CP-115 Optimisation of anti-interleukin biological therapies in psoriasis patient above 100 kg by Goldaracena, J Preciado, Goñi, N Larrea, Punset, M Coma, García, J Polo, Bayona, JI Yanguas, Bulnes, C Fontela, Elcano, R San Miguel, González, J Fernández, Zurbano, R Juanbeltz, Basarte, J Alfaro

“…BackgroundBiological agents targeting interleukin such as ustekinumab and secukinumab are strategies employed in psoriasis treatment. Ustekinumab requires…”
Get full text

DI-046 Analysis of treatment discontinuation by iatrogenesis related to DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE by Zurbano, R Juanbeltz, Juan, A Muñoz San, Marcotegui, M Rivero, Padrós, J Repáraz, de Alda, M Gracia Ruiz, Goldaracena, J Preciado, Bulnes, C Fontela, García, J Polo, de la Riva Bohigas, R, Basarte, J Alfaro

“…BackgroundDolutegravir/abacavir/lamivudine (Triumeq) is a new oral drug to treat human immunodeficiency virus (HIV) offering a single pill regimen. Treatment…”
Get full text

Position paper on the 2024 ESH clinical practice guidelines for the management of arterial hypertension in Spain by Rodilla, E., Benítez Camps, M., Castilla Guerra, L., Egocheaga Cabello, M.I., Gamarra Ortiz, J., María Tablado, M.Á., Muñoz Rivas, N., Pallarés-Carratalá, V., Polo García, J., García Donaire, J.A.

“…The 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension (ESH Guidelines 2024) have recently been…”
Get full text

PREVALENCE OF CARDIOVASCULAR DISEASE IN PATIENTS WITH METABOLIC SYNDROME IN THE IBERICAN STUDY by Cinza-Sanjurjo, S, Freire, S Yáñez, Fernández, J García, Sánchez, R López, Cepas, F Leiva, Rodríguez, R Abad, Aldana, D Rey, Alcaine, J Esturo, Castro, R Piedra, García, J Polo

“…OBJECTIVE:The general objectives of IBERICAN are to determine the prevalence and incidence of cardiovascular risk factors in Spain, as well as cardiovascular…”
Get full text

ARTERIAL HYPERTENSION, CLINICAL CHARACTERISTICS OF PATIENTS INCLUDED IN THE IBERICAN STUDY by Piera Carbonell, A.M, Prieto Díaz, M.A, Cinza Sanjurjo, S, Micó Perez, R.M, Pallarés Carratalá, V, Barquilla García, A, Llisterri Caro, J.L, Polo García, J, Romero Secin, A, González Gamarra, A, Zambrana Calví, G.D.R, Lasso Oria, V, Piñeiro Díaz, C, Gómez Montes, C, Gil Gil, I, Murillo Jelsbak, C, Panisello Royo, J.M, Gómez González, M.J, Pinto Pena, L, Ruiz García, A

“…OBJECTIVE:The general objectives of IBERICAN are to determine the prevalence and incidence of cardiovascular risk factors in Spain, as well as cardiovascular…”
Get full text

Impact of an interactive web application on the improvement of cardiovascular risk factors control. Control-RCV project by Prieto-Díaz, M A, Méndez-Rodríguez, E, Murillo-García, D, Escobar-Cervantes, C, Pallarés-Carratalá, V, Díaz-Rodríguez, A, Escribano-Serrano, J, Polo-García, J, Cinza-Sanjurjo, S

“…OBJECTIVETo ascertain the utility of an interactive web application in the improvement of cardiovascular (CV) risk control. METHODSObservational study in which…”
Get full text

4CPS-142 Effectiveness and safety of anti-IL-5 biologic agents in severe eosinophilic asthma by Calvo Arbeloa, M, Pinilla Lebrero, G, Lacalle Fabo, E, Polo García, J, Ulacia Epelde, L, Illodo Becerra, J, Fresán Restituto, D, Aldave Cobos, P, Elizondo Armendáriz, J, Sarobe Carricas, M

“…Background and importanceSevere uncontrolled asthma is characterised by poor control despite treatment with inhaled glucocorticoids (IGC) and beta2 adrenergic…”
Get full text

4CPS-112 Adherence to adalimumab, golimumab and ustekinumab therapy in inflammatory bowel disease by Calvo Arbeloa, M, Arrondo Velasco, A, Rodriguez Esquiroz, A, Polo García, J, Pinilla Lebrero, G, Tejada Marín, D, Elizondo Armendáriz, J, Sarobe Carricas, M

“…Background and importanceInflammatory bowel disease (IBD) is a group of chronic relapsing diseases. In the past 10 years, biologic agents such as adalimumab,…”
Get full text

5PSQ-050 Successful desensitisation in a patient with dasatinib hypersensitivity by Rodríguez Esquíroz, A, Polo García, J, Ulacia Epelde, L, Larrayoz Sola, B, Tejada Marín, D, Aldave Cobos, P, De La Riva Bohigas, R, Pinilla Lebrero, G, Ortega Belío, I, Sarobe Carricas, M, Elizondo Armendáriz, JJ

“…Background and importanceA 65-year-old woman with Philadelphia chromosome positive acute lymphoblastic leukaemia was treated with dasatinib 140 mg daily. After…”
Get full text

Positioning for the management of arterial hypertension in Primary Care from the critical analysis of the American (2017) and European (2018) guidelines. Spanish Society of Primary Care Physicians (SEMERGEN) by Pallarés-Carratalá, V, Divisón Garrote, J A, Prieto Díaz, M A, García Matarín, L, Seoane Vicente, M C, Molina Escribano, F, Velilla Zancada, S, Rey Aldana, D, Cinza Sanjurjo, S, Santos Altozano, C, Górriz, J L, Alonso Moreno, F J, Polo García, J, Barquilla García, A, Beato Fernández, P, Escobar Cervantes, C

“…The Scientific Societies of Primary Care, being the area in which there is a considerable prevalence of Arterial Hypertension (AHT), need to periodically…”
Get full text

Healthcare resources and needs in anticoagulant therapy for patients with nonvalvular atrial fibrillation. SAMOA Study by Barrios, V, Egocheaga-Cabello, M I, Gállego-Culleré, J, Ignacio-García, E, Manzano-Espinosa, L, Martín-Martínez, A, Mateo-Arranz, J, Polo-García, J, Vargas-Ortega, D

“…INTRODUCTION AND OBJECTIVESTo determine, in the various medical specialties, the healthcare process for anticoagulated patients with nonvalvular atrial…”
Get full text

Prevalence of hypotension in hypertensive treated patients within the Primary Care setting. The PRESCAP 2010 study by Divisón-Garrote, J.A., Prieto-Díaz, M.Á., Alonso-Moreno, F.J., Velilla-Zancada, S.M., Escobar-Cervantes, C., Llisterri-Caro, J.L., Cinza-Sanjurjo, S., Rodríguez-Roca, G.C., Polo-García, J., Pallarés-Carratalá, V., Adlbi Sibai, A., Ajenjo González, M., Alonso Moreno, F.J., Araujo Márquez, L., Arina Cordeu, A., Artigao Ródenas, L.M., Barquilla García, A., Beato Fernández, P., Caballero Pajares, V., Cabezudo Moreno, F., Calderón Montero, A., Carrasco Carrasco, E., Carrasco Martín, J.L., Carrizo Sánchez, J., Cinza Sanjurjo, S., de las Cuevas Miguel, M.P., Divisón Garrote, J.A., Elligson Garcia, S., Escobar Cervantes, C., Esteban Rojas, M.B., Fernández Toro, J.M., Frías Vargas, M., García Criado, E., Garcia Lerin, A., García Matarín, L., García Vallejo, O., Genique Martinez, R., Gil Gil, I., González Casado, I., Gorriz Teruel, J.L., Jimenez Baena, E., Llisterri Caro, J.L., Martí Canales, J.C., Mediavilla Bravo, J.J., Molina Escribano, F., Morales Quintero, S., Moyá Amengual, A., Nieto Barco, G., Pallarés Carratalá, V., Piera Carbonell, A.M., Polo García, J., Prieto Díaz, M.A., Rama Martínez, T., Redondo Prieto, M., Rey Aldana, D., Riesgo Escudero, B.E., Rodríguez Roca, G.C., Rojas Martelo, G.A., Romero Secin, A.A., Ruiz García, A., Sánchez Rodríguez, R., Sánchez Ruíz, T., Santos Altozano, C., Sanz García, F.J., Seoane Vicente, M.C., Serrano Cumplido, A., Turégano Yedro, M., Valls Roca, F., Velilla Zancada, S.M., Vicente Molinero, A.

“…AbstractObjectiveTo determine the prevalence of hypotension and associated factors in hypertensive patients treated in the Primary Care setting.Materials and…”
Get full text

Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review by Ruiz-García, A., Pallarés-Carratalá, V., Serrano-Cumplido, A., Escobar-Cervantes, C., Barquilla-García, A., Divisón-Garrote, J.A., Turégano-Yedro, M., Prieto-Díaz, M.A., Cinza-Sanjurjo, S., Alonso-Moreno, F.J., Beato-Fernández, P., García-Matarín, L., Rey-Aldana, D., Martín-Rioboó, E., Moyá-Amengual, A., Crespo-Sabarís, R., Piera-Carbonell, A., Romero-Vigara, J.C., Carrasco-Carrasco, E., Velilla-Zancada, S., Seoane-Vicente, M.C., Górriz-Teruel, J.L., Polo-García, J., Barrios, V.

“…The efficacy and safety of acetylsalicylic acid (ASA) prophylaxis for the primary prevention of atherosclerotic cardiovascular disease (ACVD) remain…”
Get full text

4CPS-031 The primary efficacy endpoint for alirocumab, reductions in low-density lipoprotein cholesterol by Polo García, J, Preciado Goldaracena, J, Larrea Goñi, N, de la Riva Bohigas, R, Illodo Becerra, JA, Rodriguez Esquiroz, A, Coma Punset, M, Aldave Cobos, P, Larrayoz Sola, B, Sarobe Carricas, M

“…BackgroundCholesterol levels in many patients with familial hypercholesterolaemia (HeFH) or dyslipidaemia are poorly controlled despite dietary changes and…”
Get full text